Jefferies Says FDA Request on ViroPharma (VPHM) Plenadren Not a Material Negative
Tweet Send to a Friend
Jefferies reiterated its Buy rating and $39 price target on ViroPharma (NASDAQ: VPHM) Wednesday despite news that the FDA did ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
